News – Apr 04, 2017

Julius Clinical Forms Alliance With Parexel

Alliance aims to strengthen global clinical trial services by aligning scientific and operational aspects of clinical trials

Utrecht, Netherlands, January 25, 2017 — Julius Clinical, a globally-operating Academic Research Organization (ARO), today announced it has entered into a non-exclusive alliance with PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services organisation. The alliance provides biopharmaceutical companies an approach to aligning scientific and operational aspects of a clinical trial.

Through this alliance, Julius Clinical and PAREXEL offer biopharmaceutical companies a unified approach for studies by providing scientific leadership, peer-to-peer networks, operational excellence and global governance. Sponsor companies can reduce the challenge of managing multiple service providers on a single study by providing seamless access to the strengths of both organisations.  

“Julius Clinical’s scientific leaders have broad experience on study committees and are able to work effectively with international networks of thought leaders and high-recruiting sites. Combining Julius Clinical’s expertise and team with PAREXEL’s global operational capabilities, will result in efficiently designed and operated trials with high scientific standards and faster recruitment, accelerating development of products,” said Aize Smink, CEO, Julius Clinical.

“PAREXEL recognises that of paramount importance to our clients is access to a broad pool of highly engaged site networks and external academic leadership and capabilities to help deliver medicines that meet patients’ needs,” said Paul Evans, Ph.D., Corporate Vice President, Global Site Solutions, PAREXEL. “This alliance will provide our clients access to the complimentary expertise of both organizations in a streamlined manner, reducing the burden of managing multiple parties and thus the associated costs.”